TY - JOUR
T1 - Increased MR-guided high intensity focused ultrasound (MR-HIFU) sonication efficiency of uterine fibroids after carbetocin administration
AU - Anneveldt, Kimberley J.
AU - van ’t Oever, Heleen J.
AU - Verpalen, Inez M.
AU - Nijholt, Ingrid M.
AU - Bartels, Wilbert
AU - Dijkstra, Jeroen R.
AU - van den Hoed, Rolf D.
AU - van ’t Veer - ten Kate, Miranda
AU - de Boer, Erwin
AU - Veersema, Sebastiaan
AU - Huirne, Judith A. F.
AU - Schutte, Joke M.
AU - Boomsma, Martijn F.
N1 - Funding Information: This research was made possible with financial support from the Innovation and Science fund of Isala Hospital Zwolle , the Netherlands. Publisher Copyright: © 2022 The Authors
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Purpose: We investigated whether administration of the long-acting uterus stimulant carbetocin increased intra-subject sonication efficiency during Magnetic Resonance image guided High Intensity Focused Ultrasound (MR-HIFU) treatment of uterine fibroids. Method: In this prospective cohort study, thirty women with symptomatic uterine fibroids undergoing MR-HIFU treatment were included between January 2018 and January 2019. Treatment started with three sonications on one side of the uterine fibroid. Subsequently, one ampoule of 1 mL carbetocin (100 µg/mL) was administered intravenously and treatment continued with three sonications on the other side of the uterine fibroid. We compared the intra-subject sonication efficiency, in terms of Energy Efficiency Factor (EEF), thermal dose volume and sonication time to ablate one cm3 of fibroid tissue, before and after carbetocin administration. Adverse events that occurred within 30 min after carbetocin administration were recorded. Results: Sonication efficiency improved after carbetocin administration as indicated by a significant decrease in EEF and sonication time (p = 0.006 and p = 0.001 respectively), and a significant increase in thermal dose volume reached (p = <0.001). Five women (16.7%) experienced temporary tachycardia, one women in combination with headache, within 30 min after carbetocin administration. Conclusion: Administration of the long-acting uterus stimulant carbetocin improved the MR-HIFU treatment intra-subject sonication efficiency in women with symptomatic uterine fibroids.
AB - Purpose: We investigated whether administration of the long-acting uterus stimulant carbetocin increased intra-subject sonication efficiency during Magnetic Resonance image guided High Intensity Focused Ultrasound (MR-HIFU) treatment of uterine fibroids. Method: In this prospective cohort study, thirty women with symptomatic uterine fibroids undergoing MR-HIFU treatment were included between January 2018 and January 2019. Treatment started with three sonications on one side of the uterine fibroid. Subsequently, one ampoule of 1 mL carbetocin (100 µg/mL) was administered intravenously and treatment continued with three sonications on the other side of the uterine fibroid. We compared the intra-subject sonication efficiency, in terms of Energy Efficiency Factor (EEF), thermal dose volume and sonication time to ablate one cm3 of fibroid tissue, before and after carbetocin administration. Adverse events that occurred within 30 min after carbetocin administration were recorded. Results: Sonication efficiency improved after carbetocin administration as indicated by a significant decrease in EEF and sonication time (p = 0.006 and p = 0.001 respectively), and a significant increase in thermal dose volume reached (p = <0.001). Five women (16.7%) experienced temporary tachycardia, one women in combination with headache, within 30 min after carbetocin administration. Conclusion: Administration of the long-acting uterus stimulant carbetocin improved the MR-HIFU treatment intra-subject sonication efficiency in women with symptomatic uterine fibroids.
KW - Efficiency
KW - High-intensity focused ultrasound ablation
KW - MR guided interventional procedures
KW - Myoma
KW - Uterine fibroids
KW - Uterus stimulant
UR - http://www.scopus.com/inward/record.url?scp=85126648561&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejro.2022.100413
DO - https://doi.org/10.1016/j.ejro.2022.100413
M3 - Article
C2 - 35340827
SN - 2352-0477
VL - 9
JO - European Journal of Radiology Open
JF - European Journal of Radiology Open
M1 - 100413
ER -